MARKET

APGE

APGE

Apogee Therapeutics Inc
NASDAQ
88.33
-1.17
-1.31%
After Hours: 87.00 -1.33 -1.51% 19:06 06/12 EDT
OPEN
89.46
PREV CLOSE
89.50
HIGH
91.24
LOW
87.39
VOLUME
1.30M
TURNOVER
--
52 WEEK HIGH
95.32
52 WEEK LOW
34.34
MARKET CAP
6.66B
P/E (TTM)
-20.3929
1D
5D
1M
3M
1Y
5Y
1D
Apogee Therapeutics Shareholders Back Board, Auditors, Compensation
TipRanks · 2d ago
Apogee Therapeutics shareholders elect Class III directors at annual meeting
PUBT · 2d ago
Analysts’ Top Healthcare Picks: Aveanna Healthcare Holdings (AVAH), Apogee Therapeutics (APGE)
TipRanks · 2d ago
Salveen Richter Reiterates Hold on Apogee; Maintains $89 Price Target Amid Long-Term Promise and Pipeline Uncertainty
TipRanks · 3d ago
Apogee Therapeutics Is Maintained at Sector Perform by RBC Capital
Dow Jones · 6d ago
RBC Capital Maintains Sector Perform on Apogee Therapeutics, Raises Price Target to $97
Benzinga · 6d ago
Apogee Therapeutics price target raised to $97 from $82 at RBC Capital
TipRanks · 6d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Apogee Therapeutics (APGE), Inventiva (IVA) and Roche Holding AG (OtherRHHVF)
TipRanks · 6d ago
More
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.

Webull offers Apogee Therapeutics Inc stock information, including NASDAQ: APGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APGE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APGE stock methods without spending real money on the virtual paper trading platform.